Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-MS
NCT07006805Phase 2Withdrawn
- Sponsor
- Cabaletta Bio
- Start
- Jun 2026
- Primary completion
- Sep 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 2 trial of resecabtagene autoleucel in multiple sclerosis (MS), sponsored by Cabaletta Bio. Planned start Jun 2026; status: withdrawn.
02
Drugs
resecabtagene autoleucel
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07006805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07006805.